RefluxStop Device and RefluxStop Deployment Tool
Implantica CE Reflux , Ltd. · Decision date Aug 20, 2026
What did the FDA approve?
FDA records P250018 as an original PMA application. The recorded decision is approval, dated Aug 20, 2026.
FDA approval order statement
REVEAL: A post-market study to assess safety and effectiveness of RefluxStop in the treatment of Gastroesophageal Reflux Disease (GERD) in general hospital practice New Enrollment PAS (Study Number RXI009, Version 7.0, dated July 30, 2026): This is a prospective, single-arm, multi-center study designed to evaluate the short- and long-term safety and effectiveness of RefluxStop in the treatment of GERD. The PAS will enroll a total of 200 patients with hiatal hernia size = 3 cm will be implanted with RefluxStop and followed for 5 years. Study participants will be enrolled at up to 10 clinical sites (minimum of 4 sites), with at least 50% of sites located in the United States and at least half of all procedures conducted at U.S. sites.The primary safety endpoint is the incidence of procedure- and device-related serious adverse device effects (SADEs), serious adverse events (SAEs) and device deficiencies (DDs) at 1 year. The rate of this composite endpoint will be compared to a performance goal (PG) of 16.2%. The primary effectiveness endpoint is pathologic acid in the lower esophagus measured by 24-hour pH monitoring (total percentage of time pH <4) at 1 yearSecondary study endpoints are as follows. Secondary safety endpoints include: incidence of procedure- and device-related SADEs, SAEs and DDs at all time points excluding at year 1, comprising month 6 as well as years 2 to 5; and incidence of procedure- or device-related Adverse Events (ADEs or AEs) at 6 months and annually thereafter up to 5 years. Secondary effectiveness endpoints include: subjects with <50% improvement of GERD-HRQL since baseline due to GERD; reduction in GERD-HRQL group score, measured at 6 months and years 1 to 5 compared to baseline; regular daily PPI usage due to GERD/acid reflux at 6 months and years 1 to 5; total percentage of time pH <4 measured by 24-hour pH monitoring at year 1; pathologic 24-hour pH monitoring and on-label device position at years 2 to 5; and incidence of inability to belch at 6 months and at years 1 to 5.The main 1-year safety and effectiveness endpoints will be analyzed as follows: The incidence of procedure- and device-related SADEs, SAEs and DDs at year 1 (primary safety endpoint) will be compared to a performance goal of <16.2%. Proportion of patients having pathologic 24-hour pH monitoring at year 1 (primary effectiveness endpoint) will be compared to a performance goal of 40%. Proportion of patients having <50% improvement of GERD-HRQL score at year 1 compared to baseline (secondary effectiveness endpoint) will be compared to a performance goal of <40%.For each of the three evaluations of 1-year endpoints, a descriptive summary will be provided on the observed rates compared to the defined performance goals.In addition, a long-term evaluation of device performance will be conducted by comparing 5-year endpoints in the PAS to long-term results following Nissen fundoplication based on literature.Descriptive analysis will be conducted on all other clinical endpoints.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Aug 20, 2026
Regulatory record facts
- Identifier
- P250018
- Regulatory pathway
- Premarket approval application
- Applicant
- Implantica CE Reflux , Ltd.
- Product code
- LEI
- Decision code
- APPR
- Decision date
- Aug 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: IMPLANT, ANTI-GASTROESOPHAGEAL REFLUX.
- Applicant
- Implantica CE Reflux , Ltd.
- Product code
- LEI
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250018 received
Application receipt date recorded by FDA.
P250018 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250018. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LEI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LINX Reflux Management SystemP100049/S040 | Torax Medical | PMA supplement | Jan 16, 2026 | FDA |
LINX Reflux Management SystemP100049/S041 | Torax Medical | PMA supplement | Jan 16, 2026 | FDA |
LINX Reflux Management SystemP100049/S038 | Torax Medical | PMA supplement | Oct 8, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Implantica CE Reflux , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sir Temi Zammit Bldg.S, Malta Life Sciences Park, San Gwann, SGN3000
Sources and methodology
- Original FDA record: P250018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
